PACTR202311679101744尚未招募1 期
RV 591: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults
The Surgeon General0 个研究点目标入组 50 人开始时间: 2023年10月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Volunteers must meet all of the following criteria to be eligible for participation:
- •1.Male or female, aged 18 to 50 years, inclusive, at the time of enrollment
- •2.Willing and able to read, sign, and date the informed consent form
- •3.Demonstrates an understanding of the study with a passing score (90% or greater) on the TOU by the third attempt, before study-related procedures are performed
- •4.Willing and able to comply with study requirements and be available to attend visits for the duration of study participation
- •5.Must have the means to be contacted by telephone for the duration of study participation
- •6.Willing to have photo or fingerprint taken for identification purposes
- •7.At low risk for HIV acquisition per investigator assessment
- •8.Agrees to refrain from donating blood or plasma outside of this study for at least the duration of study participation
- •9.Healthy based on the physician investigator’s clinical judgment after review of past medical history, medication use, vital signs, and an abbreviated physical examination
- •Note: Good health is defined by the absence of any medical condition described in the exclusion criteria in a participant with a normal abbreviated physical exam and vital signs. If the participant has a pre existing chronic condition not listed in the exclusion criteria, the condition cannot meet any of the following criteria:
- •a.first diagnosed within the 12 weeks prior to screening; or
- •b.worsening in terms of clinical outcome in the 24 weeks prior to screening; or
- •c.involves the need for medication that may pose a risk to the participant’s safety or impede assessment of adverse events or immunogenicity if they participate in the study.
- •Note: Vital signs must be normal by Appendix A Adverse Event Grading Scales, local normal ranges, or determined to be a normal variant by the physician investigator.
- •Note: An abbreviated physical exam differs from a complete exam in that it does not include a genitourinary and rectal exam.
- •10.Laboratory criteria within 45 days prior to enrollment:
- •a.Hemoglobin =11.0 g/dL for females; =12.5 g/dL for males
- •b.White blood cells (WBC) range: 3,500-9,000 cells/mm3
- •c.Platelets between 150,000 – 450,000 cells/µL
- •d.Normal liver function: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =1.25x upper limit of normal
- •e.Serum creatinine =1.25x upper limit of normal
- •f.Urinalysis: blood and protein less than 1+ and negative glucose
- •g.Negative HIV serology
- •h.Negative hepatitis B surface antigen (HbsAg)
- •i.Negative hepatitis C serology or negative hepatitis C RNA (viral load) if antibodies are detected
- •Note: Each laboratory screening test that is out of acceptable range can be repeated one time during the screening window if there is a possible alternative explanation for the out of range value or if the out of range value is due to a temporary condition that resolves within the screening visit window.
- •11.Biological Male-Specific Criteria:
- •a.Must agree to refrain from donating sperm from screening until at least 12 weeks after the last study injection
- •b.Must agree to consistently use a method of contraception (see Section 5.4.1.2) from screening until at least 12 weeks after the last study injection
- •12.Biological Female-Specific Criteria:
- •a.Not pregnant within 12 weeks prior to screening, not pregnant or breastfeeding at screening, and not planning to become pregnant or breastfeed at any time from screening until 12 weeks after t
排除标准
- •Volunteers will be excluded if any of the following apply:
- •1.Body mass index (BMI) <18.0 kg/m2 and >35.1 kg/m2
- •2.Has a condition which affects immune function, including but not limited to:
- •a.Known or suspected congenital or acquired immunodeficiency
- •b.Diabetes mellitus type 1 or type 2 (including cases controlled with diet alone)
- •Note: A history of isolated gestational diabetes is not an exclusion criterion.
- •c.Thyroid disease
- •d.Asplenia, defined as any condition resulting in the absence of a functional spleen
- •e.Conditions and diagnoses defined as potential immune-mediated medical conditions (see Appendix C)
- •3.Has a history of other chronic or clinically significant diseases or medical conditions that in the opinion of the investigator would jeopardize the safety or rights of the participant
- •Note: Includes but is not limited to sickle cell anemia, chronic hepatitis or cirrhosis, chronic urticaria, chronic cardiac disease, hypertension not controlled by medication, severe asthma, chronic pulmonary disease, renal failure, and lymphatic filariasis.
- •4.Has a history of malignancy other than squamous cell or basal cell skin cancer, unless there has been definitive surgical and/or medical treatment that is considered to have achieved a cure
- •5.Had major surgery (per the physician investigator’s judgment) within the 28 days prior to screening or has plans to have major surgery during the study
- •6.Has a personal or family history of a bleeding disorder, such as factor deficiency, coagulopathy, or platelet disorder requiring special precautions
- •7.Has a personal or family history of a blood clotting disorder, such as thrombosis with thrombocytopenia syndrome (TTS), heparin-induced thrombocytopenia and thrombosis (HITT), deep vein thrombosis, pulmonary embolism, acute myocardial infarction, and stroke
- •8.Has a condition known to increase risk of blood clotting, including but not limited to autoimmune disease, connective tissue and other inflammatory conditions, immobility, recent infection, and recent head trauma including cerebrovascular accidents (stroke)
- •9.Hepatitis B surface antigen positive at any time in the past
- •10.Untreated syphilis infection as confirmed by RPR or a similar quantitative nontreponemal test such as VDRL
- •11.Prior receipt or plans to receive any of the following:
- •a.Chronic use of therapies that may modify immune response, such as high dose inhaled and sprayed corticosteroids (>440 µg/twice daily doses of inhaled fluticasone equivalent) and systemic corticosteroids (>20 mg/day doses of prednisone equivalent for periods exceeding 10 days) within 14 days prior to enrollment or at any time during participation in this study
- •Note: The following exceptions are permitted and will not exclude study participation: use of stable low/medium doses (<440 µg/twice daily doses of inhaled fluticasone equivalent) of inhaled and sprayed corticosteroids, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on the physician investigator’s clinical judgment) at least 14 days prior to enrollment in this study. Includes other medications, which, in the opinion of the physician investigator(s), will impact the participant’s immune response.
- •b.Blood products within 120 days prior to enrollment or at any time during participation in this study
- •c.Immunoglobulins within 90 days prior t
研究者
相似试验
已完成
1 期
PK and PD study of G-CSF (BioGenomics Ltd) vs Neupogen® in healthy volunteersCTRI/2017/10/010040BioGenomics Ltd59
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CH-4051 in healthy male subjects10003816rheumatoid arthritisNL-OMON32763Chelsea Therapeutics, Inc.56
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARA 290 Administered Intravenously to Healthy Subjects, and extension in renal patientsNL-OMON33878Araim Pharmaceuticals, Inc20
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Effect of tedalinab on ECG parameters, CNS Function and Pain Perception in Healthy Subjects.Chronic pain10034606NL-OMON34384Glenmark Pharmaceuticals80
已完成
不适用
A Single-Center, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL-17A/F Nanobody) in Healthy Male SubjectsNL-OMON38479Merck KGaA32